Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.37 |
| ▸ | USP2 | O75604 | 1/20 | 0.33 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
| ▸ | NPC1 | O15118 | 1/20 | 0.30 |
| ▸ | RAB9A | P51151 | 1/20 | 0.30 |
| ▸ | HPGD | P15428 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27926383 | 0.95 | HPGD (0.33) | MEN1KMT2AUSP2HTTHPGD | |
| SCHEMBL9679186 | 0.91 | MEN1 (0.39) | MEN1KMT2AKDM4CHTTL3MBTL1 | |
| SCHEMBL7430144 | 0.86 | MEN1 (0.35) | MEN1KMT2AKDM4CHTT | |
| SCHEMBL11016937 | 0.85 | USP2 (0.46) | MEN1KMT2AUSP2KDM4CHTT | |
| SCHEMBL5595531 | 0.85 | USP2 (0.42) | MEN1KMT2AUSP2KDM4CL3MBTL1 | |
| SCHEMBL25289361 | 0.84 | MEN1 (0.36) | MEN1KMT2AKDM4CHTTL3MBTL1 | |
| SCHEMBL13616739 | 0.84 | MEN1 (0.36) | MEN1KMT2AKDM4CHTT | |
| SCHEMBL8973374 | 0.84 | MEN1 (0.36) | MEN1KMT2AKDM4CHTTL3MBTL1 | |
| SCHEMBL13460299 | 0.84 | MEN1 (0.36) | MEN1KMT2AKDM4CHTTL3MBTL1 | |
| SCHEMBL25240815 | 0.84 | MEN1 (0.36) | MEN1KMT2AKDM4CHTTL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2136620-A2 | METHODS AND COMPOSITIONS FOR TARGETING AFAP | West Virginia University C/o Office Of Technology (US) | 2009-12-30 | — | — | EP | disclosed |
| WO-2008133789-A2 | METHODS AND COMPOSITIONS FOR TARGETING AFAP | WEST VIRGINIA UNIVERSITY C/O OFFICE OF TECHNOLGOY TRANSFER WEST VIRGINIA RESEARCH CORPORATION (US) | 2008-11-06 | — | — | WO | disclosed |
| US-20080234232-A1 | Methods and compositions for targeting AFAP | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2008-09-25 | — | — | US | disclosed |
| US-4086278-A | 1-ALKENYL THIOETHERS | ORTHO PHARMACEUTICAL CORPORATION (US) | 1978-04-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080234232-A1 | Methods and compositions for targeting AFAP | ARPC5, ARPC2, ACTR2 | MEN1 4170/4885KMT2A 3260/4885USP2 1422/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.